Establishing the formulation of 0.1% diclofenac eye drops by making up solution and quantitative by High- Performance Liquid Chromatography (HPLC). Results: Natri diclofenac eye drop 0.1% mixing with phosphate buffer 0.05M get the most stability at pH=7.5. The percentage of propylene glycol and natrimetabisulfit in the formulation influenced significantly the stability of eye drop solution. The stability increased gradually if the rates of natri metabisulfit antioxygen are 0.1%; 0.2% and 0.3% or there was an increase of propylene glycol with the rate of 0%, 5% and 10%. This preparation is stable at least 5 months at temperature 50oC and protected from light. This preparation may be stable more than 20 months at room conditions 30oC and protected from light
Ophthalmic Solutions ; Diclofenac

The factors selected as an independent variable to study included antioxidant dinatri EDTA and viscosity enhancers PVP. Value of pH and percent of remained tobramycine contents after 3 months with ageing at 500C compared with primary tobramycine were selected as a dependent variable. Experimental model was designed according to model of quadratic equation including 9 formulas. The relationship between independent variables X and dependent variables Y conformed to quadratic regressive equation. Base on preliminary formulas selected, Modde 5.0 software was used to trace experimentally and deal with the results. Optimal formula of tobramycine eye drop 0.3% had stableness over 3 months at 50oC and over 12 months at normal condition
Ophthalmic Solutions ; Tobramycin

The results of study showed no significant differences on the stability of eye drop preparation containing vitamin B5 kept in neutral glass bottle and in PE vial. Light and high temperature make impact on the stability of the preparation so it needs to be kept from light in a cool place. With selected formula, the eye drop containing vitamin B5 kept in PE vial has stability at least 12 months at room conditions
Ophthalmic Solutions ; Pantothenic Acid

The purpose of this study was to investigate the therapeutic effects of early administration of 5%NaCl on corneal edema induced by intracameral injection of 2%lidocaine. All thirty eyes of 30 rabbits were randomly assigned to one of the six study groups (group A and a, group B and b, group C and c). One of tenth ml of 2%lidocaine was injected intracamerally at right eyes of thirty rabbits. In group A, they were treated with 5% NaCl every 2 hours from 24 hours after the operation. In group B, from 12 hours and in group C, immediately after the operation. In control group a, b, c, they were treated with same method except balanced salt solution instead of 5%NaCl. Central corneal thickness (CCT)was measured before operation and after operation every 6 hours until the three successive records had no demonstrable changes compared to baseline levels. A statistically significant decrease of the CCT was found in group A compared with group a from 78 hours to 138 hours postoperatively. There was a statistically significant decrease of the CCT in the group B compared with that in group b from 42 hours after the operation. Recovery time to the preoperative levels was reduced by 66 hours. There was a statistically significant decrease of the CCT in the group C compared with that in group b from 18 hours after the operation. Recovery time to the preoperative levels was reduced by 84 hours. Early initiation of treatment with 5%NaCl following intracameral injection of 2%lidocaine reduced not only the amount of the corneal edema but also the recovery to the preoperative levels.
Corneal Edema* ; Ophthalmic Solutions* ; Rabbits*

Intraocular pressure(IOP) and side effects of adding Trusopt to beta blockers was studied in 39 eyes of 22 glaucoma patients that was inadequately controlled with beta blockers alone. Routine eye examination and IOP measurement were performed before the additive therapy. Trusopt eye drops were topically applied three times a day with previously used three kinds of beta blockers. IOP was measured at 1 week, 1 month, and 3 month after the combined therapy. Mean IOP was 18.1+/-5.2mmHg before combined therapy; 15.3+/-4.0mmHg after 1week, 15.2+/-3.2mmHg after 1 month and 15.0+/-3.4mmHg after 3 month of therapy. Side effects of combined therapy were bitter taste(20.5%), burning sensation(9.6%) redness(5.1%), discomfort(5.1%), and ocular pain(5.1%). These results indicate that adding Trusopt in patients treated with beta blockers cause a further reduction of IOP that may prove to be clinically useful in glaucoma therapy.
Burns ; Glaucoma* ; Humans ; Ophthalmic Solutions

No abstract available.
Dermatitis, Allergic Contact* ; Ophthalmic Solutions*

Study on some influencing factors such as buffer, antioxidant substances to build primary formulation of tobramycin eye drops with stability over 12 months. Result: temperature and light have much influence to the stability of tobramycin and pH contents of eye drops solution. High temperature impacts clearly to the decrease of tobramycin pH and contents. The solution was stable with borate buffer more than phosphate and citrate buffer. Product samples without antioxidant substances have low remained tobramycin contents, about 70% after three months ageing. Dinatri EDTA, natri bisulfit and dinatri EDTA-natri bisulfit combination have significant effect to the stable of tobramycin content. However, dinatri EDTA choice compared with dinatri EDTA-natri bisulfit combination is the same because of dinatri EDTA effect. Dinatri EDTA has better effect to the stable of pH and increase anti-bacteria effect of benzalkonium chloride
Ophthalmic Solutions ; Tobramycin ; Drug Stability

In Korea, demand for autologous serum eye drops (ASEs) is increasing for treatment of severe dry eye diseases. However, since the MFDS (Ministry of Food and Drug Safety) does not have guidelines for use of ASEs, they are manufactured according to their own protocols by each medical institution. ASEs should be taken with caution to avoid contamination during the manufacturing process since blood must be used as a raw material and must be prepared in an open space. In this paper, we briefly review reports on ASEs and share our experience with the introduction of ASE manufacturing protocols at Severance hospital.
Eye Diseases ; Korea ; Ophthalmic Solutions*

Changes of corneal endothelial permeability and corneal thickness after instillation of topical steroid was evaluated. In five rabbits, 0.1%dexamethasone eye solution was dropped into right eyes, and in another five rabbits, 1%prednisolone acetate eye solution was dropped into right eyes, and each left eyes were used as a control with dropping of Tears Naturale(r)II (Alcon-couvreur, Belgium). After dropping eyedrops for seven days, corneal endothelial permeability and corneal thickness were measured. Mean corneal thickness changed from 371.4 micrometer to 334.2 micrometer after dropping eyedrops in 0.1%dexamethasone group, and from 375.8 micrometer to 347.8 micrometer in control group where no statistical difference was noted between the two groups. Corneal endothelial permeability was 3.58x10(-4)cm/min in 0.1%dexamethasone group, and 3.54x10(-4) cm/min in control group(p>0.05). Mean corneal thickness changed from 347.4 micrometer to 323.8 micrometer after dropping eyedrops in 1% prednisolone acetate group, and from 342.4 micrometer to 335.6 micrometer in control group. There was also no statistical difference between the two groups. Corneal endothelial permeability was 4.08x10(-4)cm/min in 1%prednisolone acetate group, and 4.26x10(-4) cm/min in control group(p>0.05). In conclusion, topical application of 0.1%dexamethasone or 1%prednisolone acetate for a short period may have no effect on corneal endothelial permeability and thickness.
Dexamethasone ; Ophthalmic Solutions ; Permeability* ; Prednisolone ; Rabbits

PURPOSE: It is known that the recurrent corneal erosion is a common disease, but its treatment is quite difficult. New concept of the pathogenesis of recurrent corneal erosion has emerged. And new therapeutic trial has been applied and its effect has been great. We review the trend of therapy to propose a new treatment modality of the disease. METHODS: Thirty-one patients who were diagnosed and treated for recurrent corneal erosion in ophthalmology department of our hospital from May.1994 to May. 2001. were selected. The distribution of age, sex, the causative factor of the disease, treatment modality, duration of therapy and the complication of disease in these patients were analyzed. RESULTS: The peak age of recurrent corneal erosion was 40s to 50s. The most common causes of recurrent corneal erosion were trauma, chronic use of eyedrops is also one of the causes of recurrent corneal erosion. The treatment includes simple eye patch (41.93%), therapeutic contact lens (22.58%) and excimer laser (35.48%). The mean duration of treatment was 10.2 days and recurrence rate was 15.94%. CONCLUSION: In conclusion, recurrent corneal erosion does have organic causative factors and the disease can be well-treated with conservative therapy such as simple patch and wearing of contact lens. The surgical techniques such as excimer laser therapy have also brought successful outcome in the patients with corneal erosions of more than 6 weeks'duration.
Humans ; Lasers, Excimer ; Ophthalmic Solutions ; Ophthalmology ; Recurrence